

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

July 22, 2004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange  
Act of 1934

July 22, 2004

-----

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----

(Exact name of registrant as specified in its charter)

|  |                             |  |
|--|-----------------------------|--|
| DELAWARE   | 1-11353                     | 13-3757370                                 |
| -----  | -----                       | -----                                      |
| (State or Other<br>Jurisdiction of<br>Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification<br>Number) |

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

-----

(Address of principal executive offices)

336-229-1127

-----

(Registrant's telephone number, including area code)

ITEM 12. Results of Operations and Financial Conditions.

Summary information of the Company dated July 22, 2004.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange  
Act of 1934, the registrant has duly caused this report to  
be signed on its behalf by the undersigned hereunto duly  
authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

-----

# Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

(Registrant)

By: /s/ BRADFORD T. SMITH

-----  
Bradford T. Smith  
Executive Vice President  
and Secretary

Date: July 22, 2004

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2003 and subsequent filings.

## LabCorp's Investment and Performance Fundamentals

- Significant Cash Generator
- EBITDA Percentage of Sales: 26.2% YTD through June 30, 2004
- Strong Balance Sheet
- Investment Grade Credit Ratings

## The Clinical Laboratory Testing Market

US Clinical Laboratory testing market is \$34-\$36 billion

- Represents 3% - 4% of all health care spending
- Grew at a CAGR of 5.5% from 1998-2001
- Influences/directs approximately 80% of health care spending
- Role and importance of testing are increasing
- Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth

## CLINICAL LABORATORY TESTING

|                           |     |
|---------------------------|-----|
| Hospitals                 | 49% |
| Independent Clinical Labs | 39% |
| Physician Offices         | 12% |

## INDEPENDENT CLINICAL LABORATORIES

|            |     |
|------------|-----|
| All others | 78% |
| LabCorp    | 22% |

Source: Company estimates, industry reports and 2003 revenue for LabCorp.

## Profile of LabCorp

- A leader in the specialty (esoteric/genomic) testing market and second largest clinical laboratory company in North America

## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

- Conducts testing on more than 350,000 specimens daily and offers more than 4,400 routine and esoteric/genomic tests
- Provides quality lab services to more than 220,000 physicians and other health care providers
- More than 23,000 employees nationwide

### MAP OF PRIMARY TESTING LOCATIONS & PSC's

#### LabCorp's Strategy

To lead the industry in achieving long-term growth and profitability by strengthening our nationwide core testing business and expanding our higher-growth, higher-value esoteric and genomic businesses.

#### Strategic Approach Connects Two Key Business Areas

##### 1) STRENGTHEN CORE TESTING

- New and Expanded Managed Care Relationships
- Selected Internal Expansion
- Acquire Core Testing Labs

##### 2) EXPAND GENOMIC AND ESOTERIC TESTING

- Internal Development of New, Medically Necessary Tests
- Acquire High-Growth, High-Value Genomic/Esoteric Labs
- License and Partner to Bring New Tests and Technology to Market

#### Demonstrated Genomic and Esoteric Strategy Execution

| INTERNAL<br>-----  | ACQUISITION<br>-----   | LICENSE/PARTNER<br>-----   |
|--|--|--|
| CMBP<br>- Cancer<br>- Genetics (Cystic Fibrosis)<br>- Infectious Disease<br>(GENOSURE) | NGI<br>- Infectious Disease:<br>Hepatitis C<br>- PCR Plasma                        | MYRIAD GENETICS<br>Predictive Tests:<br>- Breast/Ovarian and<br>Colon Cancer<br>- Melanoma<br>- Hypertension |
| CLINICAL TRIALS<br>- Drug Metabolism   | VIROMED<br>- Infectious Disease:<br>HIV, Hepatitis<br>West Nile<br>- Real-time PCR | CORRELOGIC SYSTEMS<br>- Ovarian Cancer   |
|  | PATH LABS<br>- Hospital Esoteric   | CELERA DIAGNOSTICS<br>- Breast and<br>Prostate Cancer<br>- Alzheimer's Disease                               |
|  | DIANON<br>- Cancer/Anatomic<br>Pathology   | EXACT SCIENCES<br>- Colorectal Cancer  |
|  |  | ATHEROTECH<br>- VAP Cholesterol  |
|  |  | BIO PREDICTIVE<br>- Liver Fibrosis   |

## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

### Second Quarter Operating Results (\$ in millions)

|                       | 6/30/03  | 6/30/04  |
|-----------------------|----------|----------|
|                       | -----    | -----    |
| Revenue               | \$ 743.8 | \$ 784.3 |
| Operating Expense     | \$ 600.9 | \$ 620.1 |
|                       | -----    | -----    |
| Operating Income      | \$ 142.9 | \$ 164.2 |
|                       | -----    | -----    |
| Margin                | 19.2%    | 20.9%    |
| EBITDA                | \$ 187.4 | \$ 210.8 |
|                       | -----    | -----    |
| Margin                | 25.2%    | 26.9%    |
| Bad Debt % to revenue | 7.44%    | 6.25%    |
| DSO                   | 54       | 52       |

- 1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 2nd quarter 2004 earnings release furnished on Form 8-K on July 22, 2004.

### 2004 Second Quarter Financial Achievements

- Diluted EPS of \$0.70
- EBITDA margin of 26.9% of sales
- Operating cash flow of \$146.7 million
- Increased revenues 5.5% (volume approx. 5.0%; price 0.5%)
- Repurchased approximately \$115 million of LabCorp stock

### Six-Month Operating Results (\$ in millions)

|                       | YTD<br>6/30/03 | YTD<br>6/30/04 |
|-----------------------|----------------|----------------|
|                       | -----          | -----          |
| Revenue               | \$1,455.9      | \$1,536.8      |
| Operating Expense     | \$1,188.3      | \$1,228.3      |
|                       | -----          | -----          |
| Operating Income      | \$ 267.6       | \$ 308.5       |
|                       | -----          | -----          |
| Margin                | 18.4%          | 20.1%          |
| EBITDA*               | 353.1          | 401.9          |
|                       | -----          | -----          |
| Margin                | 24.3%          | 26.2%          |
| Bad Debt % to revenue | 7.69%          | 6.49%          |
| DSO                   | 54             | 52             |

- \* For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 2nd quarter 2004 earnings release furnished on Form 8-K on July 22, 2004.

## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

### 2004 Six-Month Financial Achievements

- Increased revenues 5.6% (primarily volume)
- EBITDA margin of 26.2% of sales
- Diluted EPS of \$1.30
- Operating cash flow of \$294.3 million
- Repurchased approximately \$182 million of LabCorp stock

### Financial Performance

#### Price & Volumes: Trends by Payor Type

|                     | 2002    |            | 2003    |            | YTD Jun 2004 |            |
|---------------------|---------|------------|---------|------------|--------------|------------|
|                     | PPA     | Accessions | PPA     | Accessions | PPA          | Accessions |
|                     | \$      | millions   | \$      | millions   | \$           | millions   |
| Client (Physicians) | 26.27   | 29.6       | 27.07   | 31.7       | 26.54        | 16.5       |
| Patient             | 119.93  | 2.3        | 118.48  | 2.5        | 123.55       | 1.3        |
| Third Party         | 31.87   | 14.8       | 34.25   | 18.1       | 34.08        | 9.4        |
| (MC/MD/Insurance)   |         |            |         |            |              |            |
| Managed Care        |         |            |         |            |              |            |
| - Capitated         | 9.28    | 13.1       | 9.95    | 12.9       | 10.14        | 6.6        |
| - Fee for service   | 44.79   | 19.3       | 45.68   | 22.7       | 45.77        | 12.1       |
| Total               | 30.45   | 32.4       | 32.74   | 35.6       | 33.12        | 18.7       |
| LabCorp Total       | \$31.71 | 79.1       | \$33.43 | 87.9       | \$33.49      | 45.9       |

### Financial Performance

#### Revenue Analysis by Business Area

|                          | YTD JUN 2003         |              |                    |           |
|--------------------------|----------------------|--------------|--------------------|-----------|
|                          | Revenue<br>\$Million | Accns<br>000 | %Accns<br>to total | PPA<br>\$ |
| Genomic                  | 140.3                | 1,144.5      | 2.6%               | 122.58    |
| Identity/Gene<br>Probes  | 76.3                 | 1,742.8      | 4.0%               | 43.78     |
| All Genomic              | 216.6                | 2,887.3      | 6.6%               | 75.01     |
| Other Esoteric           | 122.9                | 3,008.1      | 6.9%               | 40.87     |
| Histology                | 97.9                 | 1,065.2      | 2.5%               | 91.94     |
| All Genomic/<br>Esoteric | 437.4                | 6,960.6      | 16.0%              | 62.85     |
| Core                     | 1,018.5              | 36,571.5     | 84.0%              | 27.85     |
| Total:                   | 1,455.9              | 43,532.1     | 100.0%             | 33.44     |

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

|                          | YTD JUN 2004         |              |                    |           | 04 vs 03               |
|--------------------------|----------------------|--------------|--------------------|-----------|------------------------|
|                          | Revenue<br>\$Million | Accns<br>000 | %Accns<br>to total | PPA<br>\$ | PPA<br>Incr/<br>(Decr) |
| Genomic                  | 144.5                | 1,237.7      | 2.7%               | 116.73    | (4.8%)                 |
| Identity/Gene<br>Probes  | 82.5                 | 1,884.2      | 4.1%               | 43.80     | 0.1%)                  |
| All Genomic              | 227.0                | 3,121.9      | 6.8%               | 72.71     | (3.1%)                 |
| Other Esoteric           | 144.3                | 3,497.5      | 7.6%               | 41.26     | 1.0%                   |
| Histology                | 98.4                 | 1,063.3      | 2.3%               | 92.55     | 0.7%                   |
| All Genomic/<br>Esoteric | 469.7                | 7,682.7      | 16.7%              | 61.14     | (2.7%)                 |
| Core                     | 1,067.1              | 38,210.6     | 83.3%              | 27.93     | 0.3%                   |
| Total:                   | 1,536.8              | 45,893.3     | 100.0%             | 33.49     | 0.2%                   |

Cash Investment Strategy

- \$90 to \$100 million in capital expenditures to support strategic growth plan
- \$50 to \$60 million for selected acquisitions (core, esoteric or anatomic pathology labs)
- Share repurchases - \$250 million stock repurchase program
- Retain flexibility in utilizing remaining cash

Financial Guidance for 2004

- Revenue growth of approximately 5% to 7% compared to 2003, including small acquisitions and/or new contracts
- EBITDA margins of approximately 25.5% of sales
- EPS in the range of \$2.55 to \$2.60
- Free cash flow\* of approximately \$475 to \$500 million (net of Cap Ex of approximately \$100 million)
- Bad debt rate of 6.25% for the 3rd and 4th quarters of 2004
- Net interest expense of approximately \$36 million
- Tax rate of 41%

\* Free cash flow is defined as operating cash flow, minus capital expenditures.

Opportunity for Investors

- Long-term industry trends appear favorable
- Visible growth drivers
- Low P/E relative to market valuations

## Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

- Significant free cash flow - multiple opportunities to increase shareholder value
- Strong balance sheet - Investment Grade ratings (S&P, Moody's)
- Solid growth potential driven by genomic strategy

### Other Financial Information

June 30, 2004

(\$ in millions)

|  | Q1 04    | Q2 04   | YTD 2004 |
|--|----------|---------|----------|
|  | -----    | -----   | -----    |
| Depreciation   | \$ 23.0  | \$ 23.3 | \$ 46.3  |
| Amortization   | \$ 10.3  | 10.5    | 20.8     |
| Capital expenditures   | \$ 20.2  | 22.4    | 42.6     |
| Cash flows from operations                                   | \$ 147.6 | 146.7   | 294.3    |
| Bad debt as a percentage of sales                            | 6.75%    | 6.25%   | 6.49%    |
| Effective interest rate on debt:                             |          |         |          |
| Zero coupon-subordinated notes                               | 2.00%    | 2.00%   | 2.00%    |
| 5 1/2% Senior Notes (including effect of interest rate swap) | 5.38%    | 5.38%   | 5.38%    |
| Revolving credit facility (weighted average)                 | 1.95%    | 2.21%   | 2.21%    |
| Days sales outstanding                                       | 54       | 52      | 52       |